277 related articles for article (PubMed ID: 28433498)
21. Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study.
Lauriello J; Claxton A; Du Y; Weiden PJ
J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32841554
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
[TBL] [Abstract][Full Text] [Related]
23. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.
Mustafa S; Bougie J; Miguelez M; Clerzius G; Rampakakis E; Proulx J; Malla A
BMC Psychiatry; 2019 Apr; 19(1):114. PubMed ID: 30991969
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
Ishigooka J; Nakamura J; Fujii Y; Iwata N; Kishimoto T; Iyo M; Uchimura N; Nishimura R; Shimizu N;
Schizophr Res; 2015 Feb; 161(2-3):421-8. PubMed ID: 25556976
[TBL] [Abstract][Full Text] [Related]
26. Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies.
Schöttle D; Clerzius G; Janetzky W; Oluboka O; Roy MA; Therrien F; Wiedemann K
Eur Psychiatry; 2022 Jul; 65(1):e42. PubMed ID: 35855645
[TBL] [Abstract][Full Text] [Related]
27. Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS).
Falissard B; Sapin C; Loze JY; Landsberg W; Hansen K
Int J Methods Psychiatr Res; 2016 Jun; 25(2):101-11. PubMed ID: 26238598
[TBL] [Abstract][Full Text] [Related]
28. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
Calabrese JR; Jin N; Johnson B; Such P; Baker RA; Madera J; Hertel P; Ottinger J; Amatniek J; Kawasaki H
Int J Bipolar Disord; 2018 Jun; 6(1):14. PubMed ID: 29886522
[TBL] [Abstract][Full Text] [Related]
29. Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.
Iwata N; Inagaki A; Sano H; Niidome K; Kojima Y; Yamada S
Adv Ther; 2020 Jul; 37(7):3324-3336. PubMed ID: 32500455
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
31. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
32. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
33. Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies.
Madera JJ; Such P; Zhao C; Baker RA
Neuropsychiatr Dis Treat; 2019; 15():1593-1604. PubMed ID: 31354275
[No Abstract] [Full Text] [Related]
34. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.
Fleischhacker WW; Baker RA; Eramo A; Sanchez R; Tsai LF; Peters-Strickland T; Perry PP; McQuade RD; Johnson BR; Carson WH; Kane JM
Schizophr Res; 2014 Nov; 159(2-3):415-20. PubMed ID: 25281992
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
36. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.
Awad G; Ng-Mak D; Rajagopalan K; Hsu J; Pikalov A; Loebel A
BMC Psychiatry; 2016 Jun; 16():176. PubMed ID: 27245981
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y
Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082
[TBL] [Abstract][Full Text] [Related]
38. BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study).
Schöttle D; Janetzky W; Therrien F; Wiedemann K
BMC Psychiatry; 2023 Mar; 23(1):162. PubMed ID: 36918846
[TBL] [Abstract][Full Text] [Related]
39. Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).
Oluboka O; Clerzius G; Janetzky W; Schöttle D; Therrien F; Wiedemann K; Roy MA
BMC Psychiatry; 2023 May; 23(1):383. PubMed ID: 37259053
[TBL] [Abstract][Full Text] [Related]
40. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis.
Sapin C; Hartry A; Kamat SA; Beillat M; Baker RA; Eramo A
Drugs Context; 2016; 5():212301. PubMed ID: 27708677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
